Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Viatris Inc (VTRS)

Viatris Inc (VTRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Viatris Earnings Preview: What to Expect

Viatris Inc. (VTRS), valued at a market cap of $14.6 billion, is a global pharmaceutical and healthcare company formed in November 2020. Headquartered in Canonsburg, Pennsylvania, it develops, manufactures and distributes a broad portfolio of generic, branded, complex generic and biosimilar medicines across more than 165 countries and territories, supplying high-quality medicines to roughly 1 billion patients globally each year. 

The global healthcare giant is expected to announce its fiscal 2025 fourth-quarter earnings soon. Ahead of the event, analysts expect VTRS to report a profit of $0.53 per share on a diluted basis, down 1.9% from $0.54 per share in the year-ago quarter. The...

Fundamentals

See More
  • Market Capitalization, $K 15,030,599
  • Shares Outstanding, K 1,151,770
  • Annual Sales, $ 14,739 M
  • Annual Income, $ -634,200 K
  • EBIT $ 287 M
  • EBITDA $ 3,180 M
  • 60-Month Beta 0.80
  • Price/Sales 1.09
  • Price/Cash Flow 2.48
  • Price/Book 0.96

Options Overview Details

View History
  • Implied Volatility 44.68% (+16.47%)
  • Historical Volatility 25.15%
  • IV Percentile 84%
  • IV Rank 42.09%
  • IV High 69.86% on 04/04/25
  • IV Low 26.38% on 01/24/25
  • Expected Move (DTE 29) 0.69 (5.20%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 1,247
  • Volume Avg (30-Day) 2,726
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 105,803
  • Open Int (30-Day) 144,562
  • Expected Range 12.55 to 13.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.53
  • Number of Estimates 4
  • High Estimate 0.54
  • Low Estimate 0.51
  • Prior Year 0.54
  • Growth Rate Est. (year over year) -1.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.90 +11.26%
on 12/23/25
13.49 -1.85%
on 01/14/26
+1.23 (+10.24%)
since 12/22/25
3-Month
9.92 +33.47%
on 11/07/25
13.49 -1.85%
on 01/14/26
+2.83 (+27.19%)
since 10/22/25
52-Week
6.85 +93.28%
on 04/10/25
13.49 -1.85%
on 01/14/26
+2.10 (+18.85%)
since 01/22/25

Most Recent Stories

More News
Viatris Earnings Preview: What to Expect

Viatris is set to report its fourth-quarter earnings soon, with analysts forecasting a slight decline in profits.

XLV : 158.29 (+0.02%)
$SPX : 6,913.35 (+0.55%)
VTRS : 13.24 (+1.46%)
3 Reasons to Sell VTRS and 1 Stock to Buy Instead

3 Reasons to Sell VTRS and 1 Stock to Buy Instead

VTRS : 13.24 (+1.46%)
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular Diseases

VTRS : 13.24 (+1.46%)
3 Cash-Producing Stocks with Questionable Fundamentals

3 Cash-Producing Stocks with Questionable Fundamentals

ACVA : 8.62 (+1.77%)
VTRS : 13.24 (+1.46%)
NPO : 240.30 (+0.52%)
3 Volatile Stocks We Keep Off Our Radar

3 Volatile Stocks We Keep Off Our Radar

VTRS : 13.24 (+1.46%)
AGCO : 114.60 (+1.00%)
SNBR : 10.13 (-3.98%)
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

PITTSBURGH , Jan. 8, 2026 /PRNewswire/ --  Viatris Inc. (Nasdaq: VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris' ongoing...

VTRS : 13.24 (+1.46%)
1 Stock Under $50 Worth Your Attention and 2 That Underwhelm

1 Stock Under $50 Worth Your Attention and 2 That Underwhelm

FITB : 50.89 (-3.73%)
TTD : 36.82 (+4.22%)
VTRS : 13.24 (+1.46%)
1 Healthcare Stock to Target This Week and 2 We Turn Down

1 Healthcare Stock to Target This Week and 2 We Turn Down

CORT : 41.30 (+13.74%)
OSCR : 15.69 (+1.88%)
VTRS : 13.24 (+1.46%)
1 Momentum Stock to Target This Week and 2 That Underwhelm

1 Momentum Stock to Target This Week and 2 That Underwhelm

VTRS : 13.24 (+1.46%)
VICR : 166.78 (+2.90%)
MTB : 217.46 (-0.78%)
1 S&P 500 Stock with Impressive Fundamentals and 2 That Underwhelm

1 S&P 500 Stock with Impressive Fundamentals and 2 That Underwhelm

ALL : 195.28 (+0.84%)
AVGO : 325.49 (-1.01%)
VTRS : 13.24 (+1.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor...

See More

Key Turning Points

3rd Resistance Point 13.64
2nd Resistance Point 13.47
1st Resistance Point 13.36
Last Price 13.24
1st Support Level 13.08
2nd Support Level 12.91
3rd Support Level 12.80

See More

52-Week High 13.49
Last Price 13.24
Fibonacci 61.8% 10.95
Fibonacci 50% 10.17
Fibonacci 38.2% 9.39
52-Week Low 6.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar